



**PRESS RELEASE**

## **IXALTIS announces new data on the effects of Litoxetine**

### **in models of urinary incontinence at the European Congress of Urology (EAU)**

Toulouse (31) / Archamps (74), 27<sup>th</sup> of March 2017. Dr. Philippe Lluel from Urosphere, a company specialized in preclinical pharmacology of urogenital tract, presented on behalf of all investigators two scientific posters at the prestigious congress of the European Association of Urology (EAU) in London, showing for the first time data on the effects of Litoxetine on the urogenital system.

A poster with oral communication took place on Friday, March 24th: "Effects of Litoxetine on urethral pressure and detrusor overactivity in anesthetized female rats."

The results of this study show that Litoxetine increases activity of the urethral sphincter and reduces the overactivity of the bladder, thus suggesting that it may play a beneficial role in the treatment of mixed urinary incontinence.

A second abstract was presented on Saturday, March 25th: "Effects of Litoxetine on acetic acid-induced detrusor overactivity and anal sphincter functions in rabbits: Comparison with duloxetine".

This study in rabbits confirmed that Litoxetine is active on both bladder hyperactivity and sphincter contraction, with magnitude of effect similar to duloxetine.

The data presented give similar and complementary results, on two different models, supporting the preclinical proof of concept for this drug candidate as a new treatment for mixed urinary incontinence.

*IXALTIS is start-up company specialized in genitourinary and renal diseases. It has acquired from Sanofi the rights to three molecules, including Litoxetine IXA-001, and completed the round A of financing in 2016.*

*Litoxetine is a highly selective serotonin (5-HT) reuptake inhibitor and a multifunctional serotonin agonist-antagonist (MSAA) under development for mixed urinary incontinence. A phase 2 dose finding study is ongoing.*

*Mixed Urinary Incontinence (MUI) is a seriously debilitating disease that affects about 400 million people worldwide and up to 50% of women over 50 years of age: no medical treatment is currently approved for this disease.*

More information and whole abstracts available in the latest news section: [www.ixaltis.com](http://www.ixaltis.com)

**IXALTIS**  
Contact : Nathalie De Valleuil  
Tel: +33 457 260 076  
[devalleuil@ixaltis.com](mailto:devalleuil@ixaltis.com)

Press Office IXALTIS  
MEDIACOM Consulting  
Contact : Thierry Barret  
+33 450 431 515

**MEDIACOM Consulting**